Late-Breaking Trials Picked For Spring ACC meeting
This article was originally published in The Gray Sheet
Executive Summary
The top trial reports at the American College of Cardiology's signature annual event will address transcatheter aortic valve replacements, atrial fibrillation ablation, heart-failure neurostimulation treatments, and more.
You may also be interested in...
New EU Filings
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
UK Guidance Tackles Social Media ‘Compliance Headache’ For Pharma
Announcing product milestones and liking LinkedIn posts are just some of the topics addressed in a long-awaited guidance that deals with the challenges prescription drug makers face in the UK when using social media.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.